Abstract

Chlamydophila pneumoniae was taxonomically separated from strain TWAR – an abbreviation of the strain isolated from humans TW-183 (material from the eye of a child in Taiwan in 1965) and AR-39 (material from a student’s throat swab with acute changes within airways in Seattle in 1983). The basis of separation of the C. pneumoniae species was the unique structure of the elementary bodies.Infection caused by C. pneumoniae is often asymptomatic (60-80% of all infections). Symptomatic infections of the upper respiratory tract relate to pharyngitis, laryngitis, sinusitis and the lower respiratory tract: bronchitis and pneumonia. C. pneumoniae infection often transforms into a chronic, clinically oligo- or asymptomatic form. The chronic inflammatory process is associated by many authors with the pathogenesis of coronary artery disease, endocarditis, atherosclerosis, hypertension, vasculitis, multiple sclerosis, sarcoidosis, and asthma.C. pneumoniae has a specific tropism and exhibits cytotoxic activity towards the airway epithelium, in which it proliferates and destroys infected cells by lysis. Entry of these bacteria to the human body leads to activation of first non-specific and then specific resistance mechanisms and the development of a local inflammatory process.Diagnosis of C. pneumoniae should be confirmed only after the exclusion of typical micro-organisms causing respiratory infections. It is important to pay attention to the fact that the epidemiological data on the incidence of C. pneumoniae infections in different age groups of patients are variable depending on the type of diagnostic methods used in the research.Chlamydia are resistant to most antibiotics that are routinely used in respiratory tract infections. These bacteria are susceptible to antibiotics that disrupt the synthesis of DNA and proteins, such as macrolides, tetracyclines, and fluoroquinolones.

References

• 1. Aslam S., Hamill R.J., Musher D.M.: Treatment of Clostridium difficile-associateddisease: old therapies and new strategies. LancetInfect. Dis., 2005; 5: 549-557
  Google Scholar
• 2. Baban S.T., Kuehne S.A., Barketi-Klai A., Cartman S.T., Kelly M.L.,Hardie K.R., Kansau I., Collignon A., Minton N.P.: The role of flagella in Clostridium difficile pathogenesis: comparison between a non-epidemicand an epidemic strain. PLoS One, 2013; 8: e73026
  Google Scholar
• 3. Backhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., Gordon J.I.:Host-bacterial mutualism in the human intestine. Science, 2005;307: 1915-1920
  Google Scholar
• 4. Bakken J.S.: Fecal bacteriotherapy for recurrent Clostridium difficileinfection. Anaerobe, 2009; 15: 285-289 5 Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., PetitJ.C.: Epidemiology of recurrences or reinfections of Clostridiumdifficile-associated diarrhea. J. Clin. Microbiol., 2000; 38: 2386-2388
  Google Scholar
• 5. Nature, 2001; 410: 1099-1103
  Google Scholar
• 6. Bartlett J.G.: Antibiotic-associated diarrhea. N. Engl. J. Med., 2002;346: 334-339
  Google Scholar
• 7. Bartlett J.G., Chang T.W., Moon N., Onderdonk A.B.: Antibioticinducedlethal enterocolitis in hamsters: studies with eleven agentsand evidence to support the pathogenic role of toxin-producingclostridia. Am. J. Vet. Res., 1978; 39: 1525-1530
  Google Scholar
• 8. Bartoloni A., Mantella A., Goldstein B.P., Dei R., Benedetti M.,Sbaragli S., Paradisi F.: In-vitro activity of nisin against clinical isolatesof Clostridium difficile. J. Chemother., 2004; 16: 119-121
  Google Scholar
• 9. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., WilcoxM.H., Rupnik M., Monnet D.L., van Dissel J.T., Kuijper E.J., ECDISStudy Group: Clostridium difficile infection in Europe: a hospital-basedsurvey. Lancet, 2011; 377: 63-73
  Google Scholar
• 10. Bengmark S.: Modulation by enteral nutrition of the acute phaseresponse and immune functions. Nutr. Hosp., 2003; 18: 1-5
  Google Scholar
• 11. Boakes S., Ayala T., Herman M., Appleyard A.N., Dawson M.J., CortésJ.: Generation of an actagardine A variant library through saturationmutagenesis. Appl. Microbiol. Biotechnol., 2012; 95: 1509-1517
  Google Scholar
• 12. Borody T.J., Khoruts A.: Fecal microbiota transplantation andemerging applications. Nat. Rev. Gastroenterol. Hepatol., 2011; 9:88-96
  Google Scholar
• 13. Bouma G., Strober W.: The immunological and genetic basis ofinflammatory bowel disease. Nat. Rev. Immunol., 2003; 3: 521-533
  Google Scholar
• 14. Bouza E., Munoz P., Alonso R.: Clinical manifestations, treatmentand control of infections caused by Clostridium difficile. Clin.Microbiol. Infect., 2005; 11 (Suppl. 4): 57-64
  Google Scholar
• 15. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., RemautE., Remon J.P., van Deventer S.J., Neirynck S., Peppelenbosch M.P.,Steidler L.: A phase I trial with transgenic bacteria expressing interleukin-10in Crohn’s disease. Clin. Gastroenterol. Hepatol., 2006;4: 754-759
  Google Scholar
• 16. Branka J.E., Vallette G., Jarry A., Bou-Hanna C., Lemarre P., VanP.N., Laboisse C.L.: Early functional effects of Clostridium difficile toxinA on human colonocytes. Gastroenterology, 1997; 112: 1887-1894
  Google Scholar
• 17. Braun M., Stuber K., Schlatter Y., Wahli T., Kuhnert P., Frey J.:Characterization of an ADP-ribosyltransferase toxin (AexT) fromAeromonas salmonicida subsp. salmonicida. J. Bacteriol., 2002; 184:1851-1858
  Google Scholar
• 18. Buffie C.G., Jarchum I., Equinda M., Lipuma L., Gobourne A.,Viale A., Ubeda C., Xavier J., Pamer E.G.: Profound alterations of intestinalmicrobiota following a single dose of clindamycin results insustained susceptibility to Clostridium difficile-induced colitis. Infect.Immun., 2012; 80: 62-73
  Google Scholar
• 19. Burrowes B., Harper D.R., Anderson J., McConville M., EnrightM.C.: Bacteriophage therapy: potential uses in the control of antibiotic-resistantpathogens. Expert Rev. Anti Infect. Ther., 2011;9: 775-785
  Google Scholar
• 20. Calabi E., Fairweather N.: Patterns of sequence conservation inthe S-layer proteins and related sequences in Clostridium difficile. J.Bacteriol., 2002; 184: 3886-3897
  Google Scholar
• 21. Cassone M., Serra P., Mondello F., Girolamo A., Scafetti S., PistellaE., Venditti M.: Outbreak of Saccharomyces cerevisiae subtype boulardiifungemia in patients neighboring those treated with a probioticpreparation of the organism. J. Clin. Microbiol., 2003; 41: 5340-5343
  Google Scholar
• 22. Castagliuolo I., Kelly C.P., Qiu B.S., Nikulasson S.T., LaMont J.T.,Pothoulakis C.: IL-11 inhibits Clostridium difficile toxin A enterotoxicityin rat ileum. Am. J. Physiol., 1997; 273: G333-G341
  Google Scholar
• 23. Castagliuolo I., LaMont J.T., Nikulasson S.T., Pothoulakis C.: Saccharomycesboulardii protease inhibits Clostridium difficile toxin A effectsin the rat ileum. Infect. Immun., 1996; 64: 5225-5232
  Google Scholar
• 24. Cerquetti M., Serafino A., Sebastianelli A., Mastrantonio P.: Bindingof Clostridium difficile to Caco-2 epithelial cell line and to extracellularmatrix proteins. FEMS Immunol. Med. Microbiol., 2002;32: 211-218
  Google Scholar
• 25. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T.,Schmidt T.M., Young V.B.: Decreased diversity of the fecal microbiomein recurrent Clostridium difficile-associated diarrhea. J. Infect.Dis., 2008; 197: 435-438
  Google Scholar
• 26. Citron D.M., Tyrrell K.L., Merriam C.V., Goldstein E.J.: Comparativein vitro activities of LFF571 against Clostridium difficile and 630other intestinal strains of aerobic and anaerobic bacteria. Antimicrob.Agents Chemother., 2012; 56: 2493-2503
  Google Scholar
• 27. Clements A.C., Magalhães R.J., Tatem A.J., Paterson D.L., RileyT.V.: Clostridium difficile PCR ribotype 027: assessing the risks of furtherworldwide spread. Lancet Infect. Dis., 2010; 10: 395-404
  Google Scholar
• 28. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonaldL.C., Pepin J., Wilcox M.H.: Clinical practice guidelines forClostridium difficile infection in adults: 2010 update by the Societyfor Healthcare Epidemiology of America (SHEA) and the InfectiousDiseases Society of America (IDSA). Infect. Control Hosp. Epidemiol.,2010; 31: 431-455
  Google Scholar
• 29. Dabard J., Dubos F., Martinet L., Ducluzeau R.: Experimental reproductionof neonatal diarrhea in young gnotobiotic hares simultaneouslyassociated with Clostridium difficile and other Clostridiumstrains. Infect. Immun., 1979; 24: 7-11
  Google Scholar
• 30. Ðapa T., Leuzzi R., Ng Y.K., Baban S.T., Adamo R., Kuehne S.A.,Scarselli M., Minton N.P., Serruto D., Unnikrishnan M.: Multiple factorsmodulate biofilm formation by the anaerobic pathogen Clostridiumdifficile. J. Bacteriol., 2013; 195: 545-555
  Google Scholar
• 31. Dethlefsen L., Huse S., Sogin M.L., Relman D.A.: The pervasiveeffects of an antibiotic on the human gut microbiota, as revealed bydeep 16S rRNA sequencing. PLoS Biol., 2008; 6: e280
  Google Scholar
• 32. Didierlaurent A., Sirard J.C., Kraehenbuhl J.P., Neutra M.R.: Howthe gut senses its content. Cell. Microbiol., 2002; 4: 61-72
  Google Scholar
• 33. Dingle T.C., Mulvey G.L., Armstrong G.D.: Mutagenic analysisof the Clostridium difficile flagellar proteins, FliC and FliD, and theircontribution to virulence in hamsters. Infect. Immun., 2011; 79:4061-4067
  Google Scholar
• 34. Dubberke E.R., Wertheimer A.I.: Review of current literature onthe economic burden of Clostridium difficile infection. Infect. ControlHosp. Epidemiol., 2009; 30: 57-66
  Google Scholar
• 35. Dupuy B., Sonenshein A.L.: Regulated transcription of Clostridiumdifficile toxin genes. Mol. Microbiol., 1998; 27: 107-120
  Google Scholar
• 36. Eckburg P.B., Bik E.M, Bernstein C.N., Purdom E., Dethlefsen L.,Sargent M., Gill S.R., Nelson K.E., Relman D.A.: Diversity of the humanintestinal microbial flora. Science, 2005; 308: 1635-1638
  Google Scholar
• 37. Eidhin D.N., Ryan A.W., Doyle R.M., Walsh J.B., Kelleher D.: Sequenceand phylogenetic analysis of the gene for surface layer protein,slpA, from 14 PCR ribotypes of Clostridium difficile. J. Med. Microbiol.,2006; 55: 69-83
  Google Scholar
• 38. Eveillard M., Fourel V., Barc M.C., Kerneis S., Coconnier M.H.,Karjalainen T., Bourlioux P., Servin A.L.: Identification and characterizationof adhesive factors of Clostridium difficile involved in adhesionto human colonic enterocyte-like Caco-2 and mucus-secretingHT29 cells in culture. Mol. Microbiol., 1993; 7: 371-381
  Google Scholar
• 39. Fagan R.P., Albesa-Jové D., Qazi O., Svergun D.I., Brown K.A.,Fairweather N.F.: Structural insights into the molecular organizationof the S-layer from Clostridium difficile. Mol. Microbiol., 2009;71: 1308-1322
  Google Scholar
• 40. Gerding D.N., Johnson S., Peterson L.R., Mulligan M.E., Silva J.Jr.: Clostridium difficile-associated diarrhea and colitis. Infect. Control.Hosp. Epidemiol., 1995; 16: 459-477
  Google Scholar
• 41. Ghantoji S.S., Sail K., Lairson D.R., DuPont H.L., Garey K.W.: Economichealthcare costs of Clostridium difficile infection: a systematicreview. J. Hosp. Infect., 2010; 74: 309-318
  Google Scholar
• 42. Giannasca P.J., Warny M.: Active and passive immunization againstClostridium difficile diarrhea and colitis. Vaccine, 2004; 22: 848-856
  Google Scholar
• 43. Giannasca P.J., Zhang Z.X., Lei W.D., Boden J.A., Giel M.A., MonathT.P., Thomas W.D.Jr.: Serum antitoxin antibodies mediate systemicand mucosal protection from Clostridium difficile disease in hamsters.Infect. Immun., 1999; 67: 527-538
  Google Scholar
• 44. Girardin S.E., Boneca I.G., Carneiro L.A., Antignac A., JéhannoM., Viala J., Tedin K., Taha M.K., Labigne A., Zähringer U., Coyle A.J.,DiStefano P.S., Bertin J., Sansonetti P.J., Philpott D.J.: Nod1 detectsa unique muropeptide from gram-negative bacterial peptidoglycan.Science, 2003; 300: 1584-1587
  Google Scholar
• 45. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A.,Thomas G., Philpott D.J., Sansonetti P.J.: Nod2 is a general sensor ofpeptidoglycan through muramyl dipeptide (MDP) detection. J. Biol.Chem., 2003; 278: 8869-8872
  Google Scholar
• 46. Gülke I., Pfeifer G., Liese J., Fritz M., Hofmann F., Aktories K.,Barth H.: Characterization of the enzymatic component of the ADPribosyltransferasetoxin CDTa from Clostridium difficile. Infect. Immun.,2001; 69: 6004-6011
  Google Scholar
• 47. Hall I.C., O’Toole E.: Intestinal flora in new-born infants: witha description of a new pathogenic anaerobe, Bacillus difficilis. Am. J.Dis. Child., 1935; 49: 390-402
  Google Scholar
• 48. Harper D.R., Anderson J., Enright M.C.: Phage therapy: deliveringon the promise. Ther. Deliv., 2011; 2: 935-947
  Google Scholar
• 49. Hasegawa M., Yamazaki T., Kamada N., Tawaratsumida K., KimY.G., Nunez G., Inohara N.: Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophilrecruitment and protection against the pathogen. J. Immunol.,2011; 186: 4872-4880
  Google Scholar
• 50. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., GoodlettD.R., Eng J.K., Akira S., Underhill D.M., Aderem A.: The innate immuneresponse to bacterial flagellin is mediated by Toll-like receptor
  Google Scholar
• 51. Hennequin C., Janoir C., Barc M.C., Collignon A., Karjalainen T.:Identification and characterization of a fibronectin-binding proteinfrom Clostridium difficile. Microbiology, 2003; 149: 2779-2787
  Google Scholar
• 52. Hennequin C., Porcheray F., Waligora-Dupriet A., Collignon A.,Barc M., Bourlioux P., Karjalainen T.: GroEL (Hsp60) of Clostridiumdifficile is involved in cell adherence. Microbiology, 2001; 147: 87-96
  Google Scholar
• 53. Hryniewicz W, Martirosian G., Ozorowski T.: Zakażenia Clostridiumdifficile: diagnostyka, terapia, profilaktyka. Narodowy InstytutLeków, Warszawa 2011
  Google Scholar
• 54. Jank T., Aktories K.: Structure and mode of action of clostridial glucosylatingtoxins: the ABCD model. Trends Microbiol., 2008; 16: 222-229
  Google Scholar
• 55. Janoir C., Pechine S., Grosdidier C., Collignon A.: Cwp84, a surface-associatedprotein of Clostridium difficile, is a cysteine proteasewith degrading activity on extracellular matrix proteins. J. Bacteriol.,2007; 189: 7174-7180
  Google Scholar
• 56. Jernberg C., Löfmark S., Edlund C., Jansson J.K.: Long-term ecologicalimpacts of antibiotic administration on the human intestinalmicrobiota. ISME J., 2007; 1: 56-66
  Google Scholar
• 57. Johnson A.P.: Drug evaluation: OPT-80, a narrow-spectrum macrocyclicantibiotic. Curr. Opin. Investig. Drugs, 2007; 8: 168-173
  Google Scholar
• 58. Johnson S., Maziade P.J., McFarland L.V., Trick W., Donskey C.,Currie B., Low D.E., Goldstein E.J.: Is primary prevention of Clostridiumdifficile infection possible with specific probiotics? Int. J. Infect.Dis., 2012; 16: e786-e792
  Google Scholar
• 59. Joshi L.T., Phillips D.S., Williams C.F., Alyousef A., Baillie L.: Contributionof spores to the ability of Clostridium difficile to adhere tosurfaces. Appl. Environ. Microbiol., 2012; 78: 7671-7679
  Google Scholar
• 60. Kaur S., Vaishnavi C., Prasad K.K., Ray P., Kochhar R.: Effect ofLactobacillus acidophilus & epidermal growth factor on experimentallyinduced Clostridium difficile infection. Indian J. Med. Res., 2011;133: 434-441
  Google Scholar
• 61. Kelly C.P.: Can we identify patients at high risk of recurrentClostridium difficile infection? Clin. Microbiol. Infect., 2012; 18 (Suppl.6): 21-27
  Google Scholar
• 62. Kim J.M., Lee J.Y., Yoon Y.M., Oh Y.K., Youn J., Kim Y.J.: NF-κBactivation pathway is essential for the chemokine expression in intestinalepithelial cells stimulated with Clostridium difficile toxin A.Scand. J. Immunol., 2006; 63: 453-460
  Google Scholar
• 63. Kirby J.M., Ahern H., Roberts A.K., Kumar V., Freeman Z., AcharyaK.R., Shone C.C.: Cwp84, a surface-associated cysteine protease,plays a role in the maturation of the surface layer of Clostridium difficile.J. Biol. Chem., 2009; 284: 34666-34673
  Google Scholar
• 64. Kotloff K.L., Wasserman S.S., Losonsky G.A., Thomas W.Jr., NicholsR., Edelman R., Bridwell M., Monath T.P.: Safety and immunogenicityof increasing doses of a Clostridium difficile toxoid vaccineadministered to healthy adults. Infect. Immun., 2001; 69: 988-995
  Google Scholar
• 65. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A.,Minton N.P.: The role of toxin A and toxin B in Clostridium difficileinfection. Nature, 2010; 467: 711-713
  Google Scholar
• 66. Kuijper E.J., Coignard B., Tull P., the ESCMID Study Group forClostridium difficile (ESGCD), EU Member States and the EuropeanCentre for Disease Prevention and Control (ECDC): Emergence ofClostridium difficile-associated disease in North America and Europe.Clin. Microbiol. Infect., 2006; 12 (Suppl. 6): 2-18
  Google Scholar
• 67. Kyne L., Hamel M.B., Polavaram R., Kelly C.P.: Health care costsand mortality associated with nosocomial diarrhea due to Clostridiumdifficile. Clin. Infect. Dis., 2002; 34: 346-353
  Google Scholar
• 68. Lavelle E.C., Murphy C., O’Neill L.A., Creagh E.M.: The role ofTLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis.Mucosal Immunol., 2010; 3: 17-28
  Google Scholar
• 69. Lawley T.D., Clare S., Walker A.W., Goluding D., Stabler R.A.,Croucher N., Mastroeni P., Scott P., Raisen C., Mottram L., FairweatherN.F., Wren B.W., Parkhill J., Dougan G.: Antibiotic treatment of Clostridiumdifficile carrier mice triggers a supershedder state, sporemediatedtransmission, and severe disease in immunocompromisedhosts. Infect. Immun., 2009; 77: 3661-3669
  Google Scholar
• 70. Lee J.S., Chung M.J., Seo J.G.: In vitro evaluation of antimicrobialactivity of lactic acid bacteria against Clostridium difficile. Toxicol.Res., 2013; 29: 99-106
  Google Scholar
• 71. Lessa F.C., Gould C.V., McDonald L.C.: Current status of Clostridiumdifficile infection epidemiology. Clin. Infect. Dis., 2012; 55(Suppl. 2): S65-S70
  Google Scholar
• 72. Lievin-Le Moal V., Servin A.L.: The front line of enteric hostdefense against unwelcome intrusion of harmful microorganisms:mucins, antimicrobial peptides, and microbiota. Clin. Microbiol.Rev., 2006; 19: 315-337
  Google Scholar
• 73. Lyerly D.M., Lockwood D.E., Richardson S.H., Wilkins T.D.: Biologicalactivities of toxins A and B of Clostridium difficile. Infect. Immun.,1982; 35: 1147-1150
  Google Scholar
• 74. Lyras D., O’Connor J.R., Howarth P.M., Sambol S.P., Carter G.P.,Phumoonna T., Poon R., Adams V., Vedantam G., Johnson S., GerdingD.N., Rood J.I.: Toxin B is essential for virulence of Clostridiumdifficile. Nature, 2009; 458: 1176-1179
  Google Scholar
• 75. Martins F.S., Nardi R.M., Arantes R.M., Rosa C.A., Neves M.J.,Nicoli J.R.: Screening of yeasts as probiotic based on capacities tocolonize the gastrointestinal tract and to protect against enteropathogenchallenge in mice. J. Gen. Appl. Microbiol., 2005; 51: 83-92
  Google Scholar
• 76. McDonald L.C., Killgore G.E., Thompson A., Owens R.C.Jr., KazakovaS.V., Sambol S.P., Johnson S., Gerding D.N.: An Epidemic, Toxingene-variant strain of Clostridium difficile. N. Engl. J. Med., 2005; 353:2433-2441
  Google Scholar
• 77. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E.: Nosocomialacquisition of Clostridium difficile infection. N. Engl. J. Med.,1989; 320: 204-210
  Google Scholar
• 78. Meessen-Pinard M., Sekulovic O., Fortier L.C.: Evidence of invivo prophage induction during Clostridium difficile infection. Appl.Environ. Microbiol., 2012; 78: 7662-7670
  Google Scholar
• 79. Merrigan M., Venugopal A., Mallozzi M., Roxas B., ViswanathanV.K., Johnson S., Gerding D.N., Vedantam G.: Human hypervirulentClostridium difficile strains exhibit increased sporulation as well asrobust toxin production. J. Bacteriol., 2010; 192: 4904-4911
  Google Scholar
• 80. Mulvey G.L., Dingle T.C., Fang L., Strecker J., Armstrong G.D.:Therapeutic potential of egg yolk antibodies for treating Clostridiumdifficile infection. J. Med. Microbiol., 2011; 60: 1181-1187
  Google Scholar
• 81. Navaneethan U., Mukewar S., Venkatesh P.G., Lopez R., ShenB.: Clostridium difficile infection is associated with worse long termoutcome in patients with ulcerative colitis. J. Crohns Colitis, 2012;6: 330-336
  Google Scholar
• 82. Pantosti A., Cerquetti M., Viti F., Ortisi G., Mastrantonio P.: Immunoblotanalysis of serum immunoglobulin G response to surfaceproteins of Clostridium difficile in patients with antibiotic-associateddiarrhea. J. Clin. Microbiol., 1989; 27: 2594-2597
  Google Scholar
• 83. Papatheodorou P., Carette J.E., Bell G.W., Schwan C., GuttenbergG., Brummelkamp T.R., Aktories K.: Lipolysis-stimulated lipoproteinreceptor (LSR) is the host receptor for the binary toxin Clostridium difficiletransferase (CDT). Proc. Natl. Acad. Sci. USA, 2011; 108: 16422-16427
  Google Scholar
• 84. Pechine S., Deneve C., Le Monnier A., Hoys S., Janoir C., CollignonA.: Immunization of hamsters against Clostridium difficile infectionusing the Cwp84 protease as an antigen. FEMS Immunol. Med. Microbiol.,2011; 63: 73-81
  Google Scholar
• 85. Pechine S., Gleizes A., Janoir C., Gorges-Kergot R., Barc M.C., DelméeM., Collignon A.: Immunological properties of surface proteinsof Clostridium difficile. J. Med. Microbiol., 2005; 54: 193-196
  Google Scholar
• 86. Pechine S., Janoir C., Boureau H., Gleizes A., Tsapis N., Hoys S., FattalE., Collignon A.: Diminished intestinal colonization by Clostridium difficileand immune response in mice after mucosal immunization with surfaceproteins of Clostridium difficile. Vaccine, 2007; 25: 3946-3954
  Google Scholar
• 87. Pechine S., Janoir C., Collignon A.: Variability of Clostridium difficilesurface proteins and specific serum antibody response in patientswith Clostridium difficile-associated disease. J. Clin. Microbiol.,2005; 43: 5018-5025
  Google Scholar
• 88. Pepin J., Alary M.E., Valiquette L., Raiche E., Ruel J., Fulop K.,Godin D., Bourassa C.: Increasing risk of relapse after treatment ofClostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis., 2005;40: 1591-1597
  Google Scholar
• 89. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X.,Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., RicciardiCastagnoliP., Layton B., Beutler B.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998;282: 2085-2088
  Google Scholar
• 90. Pothoulakis C., Gilbert R.J., Cladaras C., Castagliuolo I., SemenzaG., Hitti Y., Montcrief J.S., Linevsky J., Kelly C.P., Nikulasson S., DesaiH.P., Wilkins T.D., LaMont J.T.: Rabbit sucrase-isomaltase containsa functional intestinal receptor for Clostridium difficile toxin A. J. Clin.Invest., 1996; 98: 641-649
  Google Scholar
• 91. Pothoulakis C., LaMont J.T.: Clostridium difficile colitis and diarrhea.Gastroenterol. Clin. North Am., 1993; 22: 623-637
  Google Scholar
• 92. Rea M.C., Clayton E., O’Connor P.M., Shanahan F., Kiely B., RossR.P., Hill C.: Antimicrobial activity of lacticin 3147 against clinicalClostridium difficile strains. J. Med. Microbiol., 2007; 56: 940-946
  Google Scholar
• 93. Rea M.C., Sit C.S., Clayton E., O’Connor P.M., Whittal R.M., ZhengJ., Vederas J.C., Ross R.P., Hill C.: Thuricin CD, a posttranslationallymodified bacteriocin with a narrow spectrum of activity againstClostridium difficile. Proc. Natl. Acad. Sci. USA, 2010; 107: 9352-9357
  Google Scholar
• 94. Redelings M.D., Sorvillo F., Mascola L.: Increase in Clostridiumdifficile-related mortality rates, United States, 1999-2004. Emerg.Infect. Dis., 2007; 13: 1417-1419
  Google Scholar
• 95. Riley M.A., Wertz J.E.: Bacteriocins: evolution, ecology, and application.Annu. Rev. Microbiol., 2002; 56: 117-137
  Google Scholar
• 96. Rupnik M.: How to detect Clostridium difficile variant strains ina routine laboratory. Clin. Microbiol. Infect., 2001; 7: 417-420
  Google Scholar
• 97. Ryan A., Lynch M., Smith S.M., Amu S., Nel H.J., McCoy C.E.,Dowling J.K., Draper E., O’Reilly V., McCarthy C., O’Brien J., Ní EidhinD., O’Connell M.J., Keogh B., Morton C.O. i wsp.: A role for TLR4 inClostridium difficile infection and the recognition of surface layerproteins. PLoS Pathog., 2011; 7: e1002076
  Google Scholar
• 98. Savidge T.C., Pan W.H., Newman P., O’Brien M., Anton P.M.,Pothoulakis C.: Clostridium difficile toxin B is an inflammatory enterotoxinin human intestine. Gastroenterology, 2003; 125: 413-420
  Google Scholar
• 99. Sehr P., Joseph G., Genth H., Just I., Pick E., Aktories K.: Glucosylationand ADP ribosylation of Rho proteins: effects on nucleotidebinding, GTPase activity, and effector coupling. Biochemistry,1998; 37: 5296-5304
  Google Scholar
• 100. Sekirov I., Tam N.M., Jogova M., Robertson M.L., Li Y., LuppC., Finlay B.B.: Antibiotic-induced perturbations of the intestinalmicrobiota alter host susceptibility to enteric infection. Infect. Immun.,2008; 76: 4726-4736
  Google Scholar
• 101. Sekulovic O., Meessen-Pinard M., Fortier L.C.: Prophage-stimulatedtoxin production in Clostridium difficile NAP1/027 lysogens.J. Bacteriol., 2011; 193: 2726-2734
  Google Scholar
• 102. Semenyuk E.G., Laning M.L., Foley J., Johnston P.F., Knight K.L.,Gerding D.N., Driks A.: Spore formation and toxin production in Clostridiumdifficile biofilms. PLoS One, 2014; 9: e87757
  Google Scholar
• 103. Sheehan V.M., Sleator R.D., Fitzgerald G.F., Hill C.: Heterologousexpression of BetL, a betaine uptake system, enhances the stress toleranceof Lactobacillus salivarius UCC118. Appl. Environ. Microbiol.,2006; 72: 2170-2177
  Google Scholar
• 104. Sheehan V.M., Sleator R.D., Hill C., Fitzgerald G.F.: Improvinggastric transit, gastrointestinal persistence and therapeutic efficacyof the probiotic strain Bifidobacterium breve UCC2003. Microbiology,2007; 153: 3563-3571
  Google Scholar
• 105. Simor A.E., Bradley S.F., Strausbaugh L.J., Crossley K., NicolleL.E., SHEA Long-Term-Care Committee: Clostridium difficile in longterm-carefacilities for the elderly. Infect. Control Hosp. Epidemiol.,2002; 23: 696-703
  Google Scholar
• 106. Sleator R.D., Francis G.A., O’Beirne D., Gahan C.G., Hill C.: Betaineand carnitine uptake systems in Listeria monocytogenes affectgrowth and survival in foods and during infection. J. Appl. Microbiol.,2003; 95: 839-846
  Google Scholar
• 107. Strobel S., Mowat A.M.: Immune responses to dietary antigens:oral tolerance. Immunol. Today, 1998; 19: 173-181
  Google Scholar
• 108. Sundriyal A., Roberts A.K., Shone C.C., Acharya K.R.: Structuralbasis for substrate recognition in the enzymatic component of ADPribosyltransferasetoxin CDTa from Clostridium difficile. J. Biol. Chem.,2009; 284: 28713-28719
  Google Scholar
• 109. Szajewska H., Ruszczyński M., Radzikowski A.: Probiotics inthe prevention of antibiotic-associated diarrhea in children: a metaanalysisof randomized controlled trials. J. Pediatr., 2006; 149: 367-372
  Google Scholar
• 110. Tasteyre A., Karjalainen T., Avesani V., Delmee M., Collignon A.,Bourlioux P., Barc M.C.: Phenotypic and genotypic diversity of theflagellin gene (fliC) among Clostridium difficile isolates from differentserogroups. J. Clin. Microbiol., 2000; 38: 3179-3186
  Google Scholar
• 111. Torres J.F., Lyerly D.M., Hill J.E., Monath T.P.: Evaluation offormalin-inactivated Clostridium difficile vaccines administered byparenteral and mucosal routes of immunization in hamsters. Infect.Immun., 1995; 63: 4619-4627
  Google Scholar
• 112. Triadafilopoulos G., Pothoulakis C., O’Brien M.J., LaMont J.T.:Differential effects of Clostridium difficile toxins A and B on rabbitileum. Gastroenterology, 1987; 93: 273-279
  Google Scholar
• 113. Tucker K.D., Wilkins T.D.: Toxin A of Clostridium difficile bindsto the human carbohydrate antigens I, X, and Y. Infect. Immun.,1991; 59: 73-78
  Google Scholar
• 114. Ubeda C., Taur Y., Jenq R.R., Equinda M.J., Son T., Samstein M.,Viale A., Socci N.D., van den Brink M.R., Kamboj M., Pamer E.G.: Vancomycin-resistantEnterococcus domination of intestinal microbiotais enabled by antibiotic treatment in mice and precedes bloodstreaminvasion in humans. J. Clin. Invest., 2010; 120: 4332-4341
  Google Scholar
• 115. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., ZoetendalE.G., de Vos W.M., Visser C.E., Kuijper E.J., Bartelsman J.F., Tijssen J.G.,Speelman P., Dijkgraaf M.G., Keller J.J.: Duodenal infusion of donor fecesfor recurrent Clostridium difficile. N. Engl. J. Med., 2013; 368: 407-415
  Google Scholar
• 116. Waligora A.J., Barc M.C., Bourlioux P., Collignon A., KarjalainenT.: Clostridium difficile cell attachment is modified by environmentalfactors. Appl. Environ. Microbiol., 1999; 65: 4234-4238
  Google Scholar
• 117. Waligora A.J., Hennequin C., Mullany P., Bourlioux P., Collignon A.,Karjalainen T.: Characterization of a cell surface protein of Clostridiumdifficile with adhesive properties. Infect. Immun., 2001; 69: 2144-2153
  Google Scholar
• 118. Ward S.J., Douce G., Dougan G., Wren B.W.: Local and systemicneutralizing antibody responses induced by intranasal immunizationwith the nontoxic binding domain of toxin A from Clostridiumdifficile. Infect. Immun., 1999; 67: 5124-5132
  Google Scholar
• 119. Wemekamp-Kamphuis H.H., Sleator R.D., Wouters J.A., Hill C.,Abee T.: Molecular and physiological analysis of the role of osmolytetransporters BetL, Gbu, and OpuC in growth of Listeria monocytogenesat low temperatures. Appl. Environ. Microbiol., 2004; 70: 2912-2918
  Google Scholar
• 120. Wright A., Drudy D., Kyne L., Brown K., Fairweather N.F.: Immunoreactivecell wall proteins of Clostridium difficile identified byhuman sera. J. Med. Microbiol., 2008; 57: 750-756
  Google Scholar
• 121. Xia Y., Hu H.Z., Liu S., Pothoulakis C., Wood J.D.: Clostridium difficiletoxin A excites enteric neurones and suppresses sympatheticneurotransmission in the guinea pig. Gut, 2000; 46: 481-486
  Google Scholar

Full text